Asset
CDX-301
Revenue
No revenue reported in loaded filings.
Clinical trials (4)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02200380 | phase2 | terminated | 2014-07-01 | 2016-03-01 | Celldex Therapeutics | A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs |
| NCT03329950 | phase1 | completed | 2017-12-01 | 2022-09-13 | Celldex Therapeutics | A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies |
| NCT02302339 | phase2 | terminated | 2014-11-01 | 2018-06-14 | Celldex Therapeutics | A Study of Glembatumumab Vedotin as Monotherapy or in Combination With Immunotherapies in Patients With Advanced Melanoma |
| NCT01465139 | phase1 | completed | 2011-10-01 | 2012-11-01 | Celldex Therapeutics | A Study to Evaluate CDX-301 (rhuFlt3L) in Healthy Volunteers |
FDA applications (0)
This company has no applications containing this asset.